The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review
Open accessAbstract
It is over 50 years since the discovery of microtubules, and they have become one of the most important drug targets for anti-cancer therapies. Microtubules are predominantly composed of the protein tubulin, which contains a number of different binding sites for small-molecule drugs. There is continued interest in drug development for compounds targeting the colchicine-binding site of tubulin, termed colchicine-binding site inhibitors (CBSIs). This review highlights CBSIs discovered through diverse sources: from natural compounds, rational design, serendipitously and via high-throughput screening. We provide an update on CBSIs reported in the past three years and discuss the clinical status of CBSIs. It is likely that efforts will continue to develop CBSIs for a diverse set of cancers, and this review provides a timely update on recent developments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Structure of the αβ tubulin dimer by electron crystallography
Nogales, E., Wolf, S. G., & Downing, K. H. (1998) · Nature · doi:10.1038/34465 · Cited by 2,076
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×
“The effectiveness of chemotherapy is limited in KRAS-driven cancers and is often associated with toxicity [169].”
BackgroundInsight into tubulin regulation from a complex with colchicine and a stathmin-like domain
Ravelli, R. B. G., Gigant, B., Curmi, P. A., Jourdain, I., Lachkar, S., Sobel, A., & Knossow, M. (2004) · Nature · doi:10.1038/nature02393 · Cited by 1,630
Photopharmacology: Beyond Proof of Principle
Velema, W. A., Szymanski, W., & Feringa, B. L. (2014) · Journal of the American Chemical Society · doi:10.1021/ja413063e · Cited by 1,178
Etoposide: four decades of development of a topoisomerase II inhibitor
Hande, K. R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00228-7 · Cited by 949
Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4
Pettit, G. R., Singh, S. B., Hamel, E., Lin, C. M., Alberts, D. S., & Garcia-Kendal, D. (1989) · Experientia · doi:10.1007/bf01954881 · Cited by 786
A Roadmap to Success in Photopharmacology
Broichhagen, J., Frank, J. A., & Trauner, D. (2015) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00129 · Cited by 730
An overview of tubulin inhibitors that interact with the colchicine binding site
Lu, Y., Chen, J., Xiao, M., Li, W., & Miller, D. D. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0828-z · Cited by 709
Stuck in Division or Passing through
Rieder, C. L., & Maiato, H. (2004) · Developmental Cell · doi:10.1016/j.devcel.2004.09.002 · Cited by 657
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., & Chaplin, D. J. (1997) · PubMed · Cited by 622
Heterocycles in drugs and drug discovery
Gomtsyan, A. R. (2012) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-012-0960-z · Cited by 615
Colchicine poisoning: the dark side of an ancient drug
Finkelstein, Y., Aks, S. E., Hutson, J. R., Juurlink, D. N., Nguyen, P., Dubnov-Raz, G., Pollak, U., Koren, G., & Bentur, Y. (2010) · Clinical Toxicology · doi:10.3109/15563650.2010.495348 · Cited by 589
Targeting Mitosis in Cancer: Emerging Strategies
Dominguez-Brauer, C., Thu, K. L., Mason, J. M., Blaser, H., Bray, M. R., & Mak, T. W. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.11.006 · Cited by 495
Cabibbo, G., Enea, M., Attanasio, M., Bruix, J., Craxì, A., & Cammà, C. (2010) · Hepatology · doi:10.1002/hep.23485 · Cited by 473
Wang, L., Woods, K. W., Li, Q., Barr, K. J., McCroskey, R. W., Hannick, S. M., Gherke, L., Credo, R. B., Hui, Y.-H., Marsh, K. G., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010523x · Cited by 422
Many players in BCL-2 family affairs
Moldoveanu, T., Follis, A. V., Kriwacki, R. W., & Green, D. R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.006 · Cited by 421
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment: Miniperspective
Waghray, D., & Zhang, Q. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01457 · Cited by 400
A double-blind trial of colchicine in Beh�et's syndrome
Yurdakul, S., Mat, C., T�z�n, Y., �zyazgan, Y., Hamuryudan, V., Uysal, �., ?enocak, M., & Yazici, H. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200111)44:11<2686::aid-art448>3.0.co;2-h · Cited by 383
Downing, K. H. (2000) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.16.1.89 · Cited by 382
Fehrentz, T., Schönberger, M., & Trauner, D. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201103236 · Cited by 377
Rimassa, L., Assenat, E., Peck-Radosavljevic, M., Pracht, M., Zagonel, V., Mathurin, P., Rota Caremoli, E., Porta, C., Daniele, B., Bolondi, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30146-3 · Cited by 351
Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues
Choi, J., Kwon, H. J., Yoon, B., Kim, J., Han, S. U., Joo, H. J., & Kim, D. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb02153.x · Cited by 346
Indole, a core nucleus for potent inhibitors of tubulin polymerization
Brancale, A., & Silvestri, R. (2007) · Medicinal Research Reviews · doi:10.1002/med.20080 · Cited by 344
Martínez, G. J., Celermajer, D. S., & Patel, S. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.12.027 · Cited by 342
The biology of the combretastatins as tumour vascular targeting agents
TOZER, G. M., KANTHOU, C., PARKINS, C. S., & HILL, S. A. (2002) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2002.00211.x · Cited by 335
Munshi, N., Jeay, S., Li, Y., Chen, C.-R., France, D. S., Ashwell, M. A., Hill, J., Moussa, M. M., Leggett, D. S., & Li, C. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1173 · Cited by 326
Antimitotic natural products and their interactions with tubulin
Hamel, E. (1996) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199603)16:2<207::aid-med4>3.0.co;2-4 · Cited by 325
Prota, A. E., Danel, F., Bachmann, F., Bargsten, K., Buey, R. M., Pohlmann, J., Reinelt, S., Lane, H., & Steinmetz, M. O. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.02.005 · Cited by 314
Vascular‐targeting therapies for treatment of malignant disease
Siemann, D. W., Chaplin, D. J., & Horsman, M. R. (2004) · Cancer · doi:10.1002/cncr.20299 · Cited by 310
Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results
Rustin, G. J. S., Galbraith, S. M., Anderson, H., Stratford, M., Folkes, L. K., Sena, L., Gumbrell, L., & Price, P. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.185 · Cited by 307
Gourdeau, H., Leblond, L., Hamelin, B., Desputeau, C., Dong, K., Kianicka, I., Custeau, D., Boudreau, C., Geerts, L., Cai, S.-X., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1375.3.11 · Cited by 290
Messaoudi, S., Tréguier, B., Hamze, A., Provot, O., Peyrat, J.-F., De Losada, J. R., Liu, J.-M., Bignon, J., Wdzieczak-Bakala, J., Thoret, S., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900321u · Cited by 287
DOES COLCHICINE WORK? THE RESULTS OF THE FIRST CONTROLLED STUDY IN ACUTE GOUT
AHERN, M. J., REID, C., GORDON, T. P., McCREDlE, M., BROOKS, P. M., & JONES, M. (1987) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1987.tb01232.x · Cited by 284
Kanthou, C., & Tozer, G. M. (2002) · Blood · doi:10.1182/blood.v99.6.2060 · Cited by 280
A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs
Prota, A. E., Bargsten, K., Diaz, J. F., Marsh, M., Cuevas, C., Liniger, M., Neuhaus, C., Andreu, J. M., Altmann, K.-H., & Steinmetz, M. O. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408124111 · Cited by 279
Stähelin, H., & von Wartburg, A. (1991) · PubMed · Cited by 278
Siemann, D. W., Chaplin, D. J., & Walicke, P. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802691068 · Cited by 250
Endothelial cell proliferation as a novel approach to targeting tumour therapy
Denekamp, J. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.16 · Cited by 249
Antineoplastic Agents. 379. Synthesis of Phenstatin Phosphate1a,
Pettit, G. R., Toki, B. E., Herald, D. L., Verdier‐Pinard, P., Boyd, M. R., Hamel, E., & Pettit, R. K. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970644q · Cited by 241
Structural Basis of cis- and trans-Combretastatin Binding to Tubulin
Gaspari, R., Prota, A. E., Bargsten, K., Cavalli, A., & Steinmetz, M. O. (2017) · Chem · doi:10.1016/j.chempr.2016.12.005 · Cited by 238
Vascular Endothelium as the Vulnerable Element in Tumours
Denekamp, J. (1984) · Acta Radiologica: Oncology · doi:10.3109/02841868409136015 · Cited by 222
Free Tubulin Modulates Mitochondrial Membrane Potential in Cancer Cells
Maldonado, E. N., Patnaik, J., Mullins, M. R., & Lemasters, J. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2429 · Cited by 218
Microtubule dynamics: taking aim at a moving target
Wilson, L., & Jordan, M. A. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90119-1 · Cited by 215
Targeting tumour vasculature: the development of combretastatin A4
Griggs, J., Metcalfe, J. C., & Hesketh, R. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00224-2 · Cited by 207
Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
Stengel, C., Newman, S. P., Leese, M. P., Potter, B. V. L., Reed, M. J., & Purohit, A. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605489 · Cited by 192
Ohsumi, K., Hatanaka, T., Fujita, K., Nakagawa, R., Fukuda, Y., Nihei, Y., Suga, Y., Morinaga, Y., Akiyama, Y., & Tsuji, T. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00579-4 · Cited by 185
Mooney, C. J., Nagaiah, G., Fu, P., Wasman, J. K., Cooney, M. M., Savvides, P. S., Bokar, J. A., Dowlati, A., Wang, D., Agarwala, S. S., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0321 · Cited by 180
Keating, G. M. (2010) · Drugs · doi:10.2165/11201110-000000000-00000 · Cited by 175
Tan, L., Wang, J., Tanizaki, J., Huang, Z., Aref, A. R., Rusan, M., Zhu, S.-J., Zhang, Y., Ercan, D., Liao, R. G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403438111 · Cited by 174
Baguley, B. C., Holdaway, K. M., Thomsen, L. L., Zhuang, L., & Jonathan Zwi, L. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90391-p · Cited by 172
Vinca alkaloids: Anti-vascular effects in a murine tumour
Hill, S. A., Lonergan, S. J., Denekamp, J., & Chaplin, D. J. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90082-q · Cited by 168
Pang, Y., An, B., Lou, L., Zhang, J., Yan, J., Huang, L., Li, X., & Yin, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00480 · Cited by 161
Colchicine prophylaxis in familial Mediterranean fever: Reappraisal after 15 years
Ben‐Chetrit, E., & Levy, M. (1991) · Seminars in Arthritis and Rheumatism · doi:10.1016/0049-0172(91)90019-v · Cited by 144
Romagnoli, R., Baraldi, P. G., Salvador, M. K., Preti, D., Tabrizi, M. A., Brancale, A., Fu, X., Li, J., Zhang, S., Hamel, E., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2013979 · Cited by 142
The first international conference on vascular targeting: meeting overview.
Thorpe, P. E., Chaplin, D. J., & Blakey, D. C. (2003) · PubMed · Cited by 138
Li, W., Xu, F., Wen, S., Sun, H., Yao, H., Ma, C., Xu, S., Yao, H., Zhu, Z., Yang, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01755 · Cited by 135
Döhle, W., Jourdan, F. L., Menchon, G., Prota, A. E., Foster, P., Mannion, P., Hamel, E., THOMAS, M. P., Kasprzyk, P. G., Ferrandis, E., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01474 · Cited by 133
The development of combretastatin A4 phosphate as a vascular targeting agent
Chaplin, D. J., & Hill, S. A. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)03924-x · Cited by 132
Synthesis and Evaluation of Azetidinone Analogues of Combretastatin A-4 as Tubulin Targeting Agents
O’Boyle, N. M., Carr, M. J., Greene, L. M., Bergin, O. E., Nathwani, S. M., McCabe, T., Lloyd, D. G., Zisterer, D. M., & Meegan, M. J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101115u · Cited by 132
Self-citationMET: A Critical Player in Tumorigenesis and Therapeutic Target
Graveel, C. R., Tolbert, D., & Vande Woude, G. F. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009209 · Cited by 128
Chen, J., Ahn, S., Wang, J., Lü, Y., Dalton, J. T., Miller, D. D., & Li, W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300564b · Cited by 123
Siemann, D. W., & Shi, W. (2008) · PubMed · Cited by 102
Matei, D. E., Schilder, J. M., Sutton, G. P., Perkins, S. M., Breen, T., Quon, C. Y., & Sidor, C. F. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.05.042 · Cited by 101
Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma
Kim, T. J., Ravoori, M. K., Landen, C. N., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4018 · Cited by 98
Zhang, L., Wu, L., Raymon, H. K., Chen, R. S., Corral, L. G., Shirley, M. A., Narla, R. K., Gamez, J., Muller, G. W., Stirling, D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2083 · Cited by 93
Engel, J., Lategahn, J., & Rauh, D. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00475 · Cited by 91
Khelifi, I., Naret, T., Renko, D. Z., Hamzé, A., Bernadat, G., Bignon, J. S., Lenoir, C., Dubois, J., Brion, J., Provot, O., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.11.012 · Cited by 86
Bai, Z., Gao, M., Zhang, H., Guan, Q., Xu, J., Li, Y., Qi, H., Li, Z., Zuo, D., Zhang, W., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.016 · Cited by 83
Andreu, J. M., Perez-Ramirez, B., Gorbunoff, M. J., Ayala, D., & Timasheff, S. N. (1998) · Biochemistry · doi:10.1021/bi9728553 · Cited by 82
Current aspects of colchicine therapy -- classical indications and new therapeutic uses.
Lange, U., Schumann, C., & Schmidt, K. L. (2001) · PubMed · Cited by 82
Wang, Q., Arnst, K. E., Wang, Y., Kumar, G., Ma, D., White, S. W., Miller, D. D., Li, W., & Li, W. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00706 · Cited by 82
Combretastatins: More Than Just Vascular Targeting Agents?
Greene, L. M., Meegan, M. J., & Zisterer, D. M. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.226225 · Cited by 81
Tumour vascular disrupting agents: combating treatment resistance
Tozer, G. M., Kanthou, C., Lewis, G., Prise, V. E., Vojnovic, B., & Hill, S. A. (2008) · British Journal of Radiology · doi:10.1259/bjr/36205483 · Cited by 79
Dong, M., Liu, F., Zhou, H., Zhai, S., & Yan, B. (2016) · Molecules · doi:10.3390/molecules21101375 · Cited by 77
Chen, J., Li, C.-M., Wang, J., Ahn, S., Wang, Z., Lü, Y., Dalton, J. T., Miller, D. D., & Li, W. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.084 · Cited by 74
Lindamulage, I. K. S., Vu, H.-Y. T., Karthikeyan, C., Knockleby, J., Lee, Y.-F., Trivedi, P., & Lee, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-10972-0 · Cited by 74
Yang, J., Yan, W., Yu, Y., Wang, Y., Yang, T., Xue, L., Yuan, X., Long, C., Liu, Z., Chen, X., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001658 · Cited by 69
Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198
LaVallee, T. M., Burke, P. A., Swartz, G. M., Hamel, E., Agoston, G. E., Shah, J., Suwandi, L., Hanson, A. D., Fogler, W. E., Sidor, C. F., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0107 · Cited by 67
Hua, J., Sheng, Y., Pinney, K. G., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80778-x · Cited by 66
Cummings, J., Zelcer, N., Allen, J. D., Yao, D., Boyd, G. W., Malliepaard, M., Friedberg, T., Smyth, J. F., & Jodrell, D. I. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.07.019 · Cited by 66
Greene, T. F., Wang, S., Greene, L. M., Nathwani, S. M., Pollock, J. K., Malebari, A. M., McCabe, T., Twamley, B., O’Boyle, N. M., Zisterer, D. M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01086 · Cited by 65
Self-citationRymer, J. A., & Newby, L. K. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.07.001 · Cited by 65
Aoyama, A., Katayama, R., Oh‐hara, T., Sato, S., Okuno, Y., & Fujita, N. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0462 · Cited by 63
Yang, Z., Wu, W., Wang, J., Liu, L., Li, L., Yang, J., Wang, G., Cao, D., Zhang, R., Tang, M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500849z · Cited by 59
Photoresponsive azo-combretastatin A-4 analogues
Rastogi, S. K., Zhao, Z., Barrett, S. L., Shelton, S. D., Zafferani, M., Anderson, H. E., Blumenthal, M. O., Jones, L. R., Wang, L., Li, X., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.012 · Cited by 59
Morinaga, Y., Suga, Y., Ehara, S., Harada, K., Nihei, Y., & Suzuki, M. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01419.x · Cited by 54
Herdman, C. A., Strecker, T. E., Tanpure, R. P., Chen, Z., Winters, A., Gerberich, J., Liu, L., Hamel, E., Mason, R. P., Chaplin, D. J., et al. (2016) · MedChemComm · doi:10.1039/c6md00459h · Cited by 49
O’Boyle, N. M., Carr, M. J., Greene, L. M., Keely, N. O., Knox, A. J. S., McCabe, T., Lloyd, D. G., Zisterer, D. M., & Meegan, M. J. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.039 · Cited by 47
Self-citationPasquier, E., Sinnappan, S. M., Munoz, M. A., & Kavallaris, M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0894 · Cited by 47
The Role of Colchicine in Acute Coronary Syndromes
Vaidya, K., Martínez, G., & Patel, S. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.07.023 · Cited by 43
Cao, D., Han, X., Wang, G., Yang, Z., Peng, F., Ma, L., Zhang, R., Ye, H., Tang, M., Wu, W., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.01.007 · Cited by 42
Synthesis and antitumor-evaluation of cyclopropyl-containing combretastatin analogs
Fürst, R., Zupkó, I., Berényi, Á., Ecker, G. F., & Rinner, U. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.10.064 · Cited by 41
Romagnoli, R., Oliva, P., Salvador, M. K., Camacho, M. E., Padroni, C., Brancale, A., Ferla, S., Hamel, E., Ronca, R., Grillo, E., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111577 · Cited by 41
Dupuis, M. L., Flego, M., Molinari, A., & Cianfriglia, M. (2003) · HIV Medicine · doi:10.1046/j.1468-1293.2003.00169.x · Cited by 39
Synthesis of etoposide phosphate, BMY-40481: A water-soluble clinically active prodrug of etoposide
Saulnier, M. G., Langley, D. R., Kadow, J. F., Senter, P. D., Knipe, J. O., Tun, M. M., Vyas, D. M., & Doyle, T. W. (1994) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)80285-7 · Cited by 38
1,2,3,4-Tetrahydro-2-thioxopyrimidine analogs of combretastatin-A4
Lee, L., Davis, R., Vanderham, J., Hills, P., Mackay, H., Brown, T., Mooberry, S. L., & Lee, M. (2008) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2007.11.030 · Cited by 36
Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy
Arnst, K. E., Wang, Y., Lei, Z., Hwang, D., Kumar, G., Ma, D., Parke, D. N., Chen, Q., Yang, J., White, S. W., et al. (2019) · Molecular Pharmacology · doi:10.1124/mol.118.114801 · Cited by 36
Schmitt, F., Gosch, L. C., Dittmer, A., Rothemund, M., Mueller, T., Schobert, R., Biersack, B., Volkamer, A., & Höpfner, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020383 · Cited by 34
Lai, Q., Wang, Y., Wang, R., Lai, W., Tang, L., Tao, Y., Liu, Y., Zhang, R., Huang, L., Xiang, H., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.05.010 · Cited by 33
O’Boyle, N. M., Greene, L. M., Keely, N. O., Wang, S., Cotter, T. S., Zisterer, D. M., & Meegan, M. J. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.01.016 · Cited by 25
Self-citationXiao, D., Deguchi, A., Gundersen, G. G., Oehlen, B., Arnold, L. D., & Weinstein, I. B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0260 · Cited by 24
O’Boyle, N. M., Ana, G., Kelly, P. M., Nathwani, S. M., Noorani, S., Fayne, D., Bright, S. A., Twamley, B., Zisterer, D. M., & Meegan, M. J. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob00558g · Cited by 24
Self-citationStilbenophane Analogues of Deoxycombretastatin A-4
Mateo, C., Pérez‐Melero, C., Peláez, R., & Medarde, M. (2005) · The Journal of Organic Chemistry · doi:10.1021/jo0508393 · Cited by 22
Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia
Winn, B. A., Shi, Z., Carlson, G. J., Wang, Y., Nguyen, B. L., Kelly, E. M., Ross, R., Hamel, E., Chaplin, D. J., Trawick, M. L., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.11.093 · Cited by 20
CC-5079: A Small Molecule with MKP1, Antiangiogenic, and Antitumor Activity
Vu, H. N., Miller, W. J., O'Connor, S. A., He, M., Schafer, P. H., Payvandi, F., Muller, G. W., Stirling, D., & Libutti, S. K. (2009) · Journal of Surgical Research · doi:10.1016/j.jss.2009.01.031 · Cited by 16
Wang, S., Malebari, A. M., Greene, T. F., O’Boyle, N. M., Fayne, D., Nathwani, S. M., Twamley, B., McCabe, T., Keely, N. O., Zisterer, D. M., et al. (2019) · Pharmaceuticals · doi:10.3390/ph12020056 · Cited by 16
Self-citation
Cited by
Regulation of microtubule dynamics, mechanics and function through the growing tip
Gudimchuk, N. B., & McIntosh, J. R. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00399-x · Cited by 369
Horin, L. J., Sonnett, M., Li, B., & Mitchison, T. J. (2025) · doi:10.1101/2025.01.22.632572 · Cited by 4
Metadata
- Authors
- McLoughlin, E. C., & O’Boyle, N. M.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2020-01-03
- Volume
- 13
- Issue
- 1
- Pages
- 8
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W2996972660
- Cited by
- 316
- References
- 107
- FWCI
- 19.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.